Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Patients With Relapsed EOC After Treatment With PARPi

NCT05126342 is registered in ClinicalTrials.gov with AGO Research GmbH as lead sponsor.

NCT NCT05126342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05126342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Patients With Relapsed EOC After Treatment With PARPi
Lead sponsor
AGO Research GmbH
Phase
Phase 2
Overall status
Withdrawn
Start date
November 1, 2023
Completion date
November 1, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary peritoneal cancer, recurrent fallopian tube cancer, recurrent ovarian cancer